In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on the off-label use of photodynamic therapy. Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, is a member of Soligenix's scientific advisory board, and was a participating investigator in the Phase 3 FLASH trial of HyBryte in CTCL. Dr. Bhatia's presentation included a comparison of efficacy results seen thus far for HyBryte to those from a Phase 3 trial of Valchlor , an FDA-approved second line therapy for the treatment of CTCL. Those results show that HyBryte appears to have a faster onset of activity than Valchlor and provides solid support for what we believe will be a positive outcome from the ongoing Phase 3 FLASH2 trial of HyBryte. We anticipate continued updates from the company regarding the FLASH2 trial throughout 2025.
